Vertraagde tijd
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
0,042 SGD | -2,33% | -.--% | -33,33% |
15/02 | USP ontvangt vordering voor juridische kosten | MT |
23/01 | ANI Pharmaceuticals introduceert Pentoxifylline tabletten met verlengde afgifte | MT |
Omzet 2020 | 36,9 mln. 27,34 mln. 25,39 mln. | Omzet 2021 | 34,08 mln. 25,25 mln. 23,45 mln. | Marktkapitalisatie | 4,69 mln. 3,48 mln. 3,23 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2020 | -6 mln. -4,45 mln. -4,13 mln. | Nettowinst (verlies) 2021 | -1 mln. -741K -688K | EV/omzet 2020 | 1,25 x |
Nettoschuld 2020 | 39,14 mln. 29,01 mln. 26,94 mln. | Nettoschuld 2021 | 35,49 mln. 26,3 mln. 24,43 mln. | EV/omzet 2021 | 1,18 x |
K/w-verhouding 2020 |
-1,1
x | K/w-verhouding 2021 |
-3,75
x | Werknemers | 166 |
Dividendrendement 2020 * |
-
| Dividendrendement 2021 |
-
| Vrij verhandelbaar | 84,13% |
1 dag | -2,33% | ||
3 maanden | -38,24% | ||
6 maanden | -53,33% | ||
Lopend jaar | -33,33% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chee Seng Shek
CEO | Chief Executive Officer | 62 | 02/12 |
Kheng Jen Ng
DFI | Director of Finance/CFO | 31 | 29-03-22 |
Ai Juan Zhang
SEC | Corporate Secretary | - | 17-06-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chee Seng Shek
CEO | Chief Executive Officer | 62 | 02/12 |
Mong Keang Sim
BRD | Director/Board Member | 55 | 02/12 |
Chung Khang Chan
CHM | Chairman | 45 | 02/12 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-33,33% | 2,81 mln. | |
-14,50% | 742 mln. | |
-16,69% | 410 mln. | |
+0,88% | 53,08 mln. | |
-12,86% | 50,95 mln. |